Download PDFPDF
Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address